Compare INTG & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTG | PRPO |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 32.4M |
| IPO Year | N/A | N/A |
| Metric | INTG | PRPO |
|---|---|---|
| Price | $27.85 | $24.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.1K | 7.7K |
| Earning Date | 02-13-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,385,000.00 | $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.82 | ★ 30.95 |
| 52 Week Low | $9.57 | $3.90 |
| 52 Week High | $42.50 | $28.50 |
| Indicator | INTG | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 58.64 |
| Support Level | $25.00 | $22.40 |
| Resistance Level | $28.40 | $24.92 |
| Average True Range (ATR) | 1.92 | 1.34 |
| MACD | 0.32 | -0.03 |
| Stochastic Oscillator | 73.99 | 68.46 |
The Intergroup Corp is an us-based company operating in the real estate sector. It is formed to buy, develop, operate, rehabilitate and dispose of real property of various types and descriptions, and to engage in other related business and investment activities. The company operates through three segments namely Hotel Operations, Real Estate Operations, and Investment Transactions. The Hotel Operations segment which generates the majority of the revenue covers the operation of the Hilton hotel and garage. The Real Estate Operations segment consists of the operation of multifamily rental properties whereas the Investment Transactions segment includes an investment of cash in marketable securities and other investments.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.